These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 1564836)
1. [A new interferon-alpha assay system including indirect antitumor effect. Basic and clinical study of renal cell carcinoma]. Yoshihiro S Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):338-47. PubMed ID: 1564836 [TBL] [Abstract][Full Text] [Related]
2. Direct and indirect effects of human interferon alpha on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects. Matsuyama H; Yoshihiro S; Ohmoto Y; Yamamoto N; Naito K Cancer Immunol Immunother; 1993 Jul; 37(2):84-8. PubMed ID: 8319245 [TBL] [Abstract][Full Text] [Related]
3. Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro. Kurisu H; Matsuyama H; Ohmoto Y; Shimabukuro T; Naito K Cancer Immunol Immunother; 1994 Oct; 39(4):249-53. PubMed ID: 7954527 [TBL] [Abstract][Full Text] [Related]
4. [Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay--single and combination effect with cancer chemotherapeutic agent]. Ohmura K; Tsukamoto T Hinyokika Kiyo; 1989 May; 35(5):737-47. PubMed ID: 2801371 [TBL] [Abstract][Full Text] [Related]
5. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma. Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818 [TBL] [Abstract][Full Text] [Related]
6. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285 [TBL] [Abstract][Full Text] [Related]
7. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693 [TBL] [Abstract][Full Text] [Related]
8. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625 [TBL] [Abstract][Full Text] [Related]
9. [Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-alpha in patients with renal cell carcinoma]. Kubota S Nihon Hinyokika Gakkai Zasshi; 1992 Nov; 83(11):1781-8. PubMed ID: 1479751 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of human natural interferon-alpha and mismatched double-stranded RNA against a human renal cell carcinoma xenograft. Hubbell HR; Pequignot EC; Shanabrook KR; Carter WA; Williams RD; Strayer DR Anticancer Res; 1990; 10(3):795-801. PubMed ID: 2369093 [TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid. Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310 [TBL] [Abstract][Full Text] [Related]
13. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686 [TBL] [Abstract][Full Text] [Related]
14. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Hathorn RW; Tso CL; Kaboo R; Pang S; Figlin R; Sawyers C; deKernion JB; Belldegrun A Cancer; 1994 Oct; 74(7):1904-11. PubMed ID: 7521786 [TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil. Imai T; Katagiri A; Saito K; Tomita Y Cancer Lett; 1995 Aug; 94(2):191-7. PubMed ID: 7634247 [TBL] [Abstract][Full Text] [Related]
16. Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha. Bassukas ID; Hofmockel G; Maurer-Schultze B Anticancer Res; 1994; 14(1A):237-45. PubMed ID: 8166454 [TBL] [Abstract][Full Text] [Related]
17. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α. Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Dejima T; Tanaka S; Itsumi M; Eto M; Naito S Cancer Immunol Immunother; 2013 Mar; 62(3):517-27. PubMed ID: 23052245 [TBL] [Abstract][Full Text] [Related]
18. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Morita T; Tokue A Cancer Chemother Pharmacol; 1999; 44(2):91-6. PubMed ID: 10412941 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of continuous subcutaneous infusion therapy using interferon alpha and the possible prognostic indicator of TNF-alpha in renal cell carcinoma. Matsuyama H; Yamamoto M; Yoshihiro S; Ohmoto Y; Naito K Int J Urol; 1997 Sep; 4(5):447-50. PubMed ID: 9354944 [TBL] [Abstract][Full Text] [Related]
20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]